CELL & GENE THERAPY INSIGHTS

DECENTRALIZED/DISTRIBUTED ADVANCED THERAPY MANUFACTURING

SPOTLIGHT

REVIEW

Strategic IP landscapes for automated bioreactors in decentralized cell and gene therapy manufacturing: a concise overview

Will Rosellini, Oscar Chow, and Oscar Hernandez

The shift towards decentralized Cell and Gene Therapy (CGT) manufacturing necessitates advanced automated bioreactors. This manuscript analyzes the strategic intellectual property (IP) landscape driving these pivotal technologies. We observe a robust 7.52% CAGR in patent activity over five years, with significant innovation emerging from Asian hubs, notably China and South Korea, challenging traditional dominance. Key IP concentration areas include core bioreactor hardware, single-use technologies (SUTs), microfluidic systems, and the sophisticated integration of software, automation, and AI/ML for process control. The competitive landscape features established bioprocessing entities offering holistic solutions, while specialized providers focus on disruptive advancements. A predominant strategy involves creating 'closed ecosystems' through multi-layered IP, fostering platform lock-in. Significant 'white space' opportunities persist in edge-compatible software, advanced automated sterility assurance, and AI-driven real-time GMP compliance. Capitalizing on these requires a proactive, hybrid IP strategy aligned with global regulatory frameworks. Ultimately, astute navigation of this IP terrain is crucial for leadership in accessible, scalable, and compliant decentralized CGT manufacturing.

Cell & Gene Therapy Insights 2025; 11(8), 867–896· DOI: 10.18609/cgti.2025.099

INTRODUCTION

The intellectual property (IP) landscape for automated bioreactors in decentralized cell and gene therapy (CGT) manufacturing is characterized by intense innovation and strategic positioning by a range of players. This article details this landscape, mapping key technology areas of patent concentration, identifying dominant patent assignees, and delineating their respective strengths in specific niches. The analysis confirms that IP is a foundational asset, driving market differentiation, enabling

platform lock-in (making it difficult and costly to switch to a competitor's offering), and underpinning the significant investments required to develop and commercialize these sophisticated manufacturing solutions. Far from being merely a defensive shield for inventions, IP in this domain functions as a potent strategic weapon, crucial for establishing market dominance and justifying the substantial capital required in this high-cost, high-complexity field.

A pivotal shift towards decentralized CGT manufacturing models—including point-of-care (POC) and hub-and-spoke networks—is underway, driven by the need to improve patient access and cost–effectiveness. Automated bioreactors are critical enablers of this transition, and their associated IP is becoming a key determinant of competitive advantage. The push toward decentralization creates a strong demand for specific innovations, particularly for compact, user-friendly systems that can consistently meet Good Manufacturing Practice (GMP) standards. This demand drives the development of new intellectual property.

Global patent activity is robust, with a compound annual growth rate (CAGR) of approximately 7.52% over the last 5 years [1]. There is also a notable rise in innovation from Asian hubs like China and South Korea, challenging traditional US and European dominance [2,3]. Key technological trends include the ongoing refinement of traditional stirred-tank single-use reactors (SSTRs) by established giants (e.g., Danaher/Cytiva, Sartorius, Thermo Fisher Scientific) and the emergence of microfluidic systems driven by academic spin-offs and startups for niche applications. Single-use technologies (SUTs) remain a critical IP battleground, with companies leveraging proprietary designs that result in a market dynamic where customers are reliant on vendor-specific consumables.

Increasingly, the 'intelligence' of these systems—software, automation, process analytical technology (PAT), and artificial intelligence/machine learning (AI/ML)—is a major focus of IP [4]. This signals a shift in value creation and control towards the data and algorithms that manage these complex systems. Integrated end-to-end cell processing platforms, often termed 'GMP-in-a-box' systems (e.g., Lonza Cocoon®, Miltenyi Biotec CliniMACS Prodigy®, Cellares Cell Shuttle™, and Ori Biotech IRO® Platform), represent a dominant paradigm for decentralized applications, with companies using IP to create highly integrated, proprietary ecosystems.

Significant 'white space' (areas with untapped innovation potential) opportunities for innovation and IP generation persist, particularly in edge-compatible bioreactor software and analytics, advanced automated cleaning/sterilization for reusables or enhanced sterility assurance for SUTs, and AI-driven real-time GMP assurance. Capitalizing on these requires not only technological novelty but also alignment with evolving global regulatory frameworks.

Strategic recommendations for innovators include focusing on validated white spaces, adopting hybrid IP strategies for software/AI, and designing for modularity and regulatory adaptability. Investors should scrutinize IP portfolios for defensible control points and ecosystem control potential. Ultimately, the companies that successfully navigate and shape this IP terrain will define the future of accessible, scalable, and compliant decentralized CGT manufacturing.

To comprehensively explore this strategic domain, this paper is structured to guide the reader from the foundational market drivers to actionable strategic insights. First, it will establish the strategic imperative for decentralization in CGT and the role of automated bioreactors as critical enablers. Second, the analysis will map the global IP landscape, examining key growth trends, geographical innovation hubs, and the primary technology categories

attracting patent activity. Third, it will detail the competitive landscape by profiling the leading patent holders and their areas of niche dominance. Following this, the paper will deconstruct the specific IP strategies used to achieve market control, such as the creation of integrated ecosystems and protection of foundational technologies. Subsequently, it will identify and analyze key 'white space' opportunities for future innovation. Finally, the analysis culminates in a set of strategic recommendations for innovators and investors, translating these IP insights into tangible business opportunities.

THE EVOLVING LANDSCAPE OF AUTOMATED BIOREACTORS IN DECENTRALIZED CGT MANUFACTURING

The strategic imperative of decentralization in CGT

The manufacturing paradigm for CGTs) is undergoing a fundamental transformation, moving from traditional, large-scale centralized facilities towards more agile and patient-proximate decentralized models [5]. These emerging models encompass POC manufacturing, where therapies are produced at or near the site of patient treatment; hub-and-spoke networks, which combine centralized production capabilities with regional distribution and finishing sites; and CDMO-enabled distributed production, leveraging specialized third-party facilities closer to patient populations [6].

This strategic shift is propelled by compelling needs: to enhance patient access to these life-saving treatments, to mitigate the significant logistical complexities inherent in centralized production, and ultimately, to improve the overall cost–effectiveness of CGTs. Critically, this shift also confronts the primary commercial barrier of high cost per dose—often running into hundreds of thousands of dollars—which currently limits widespread adoption. Decentralization and automation are key strategies to drive down these costs by reducing reliance on manual labor and extensive, centralized cleanroom facilities. Furthermore, this model directly enhances the therapeutic value for patients by significantly reducing the 'vein-to-vein' time crucial for efficacy in aggressive diseases and by easing the immense travel and logistical burden placed on patients and their families. The logistical demands and critical 'vein-to-vein' time for autologous therapies, where a patient's own cells are harvested, modified, and re-infused, are particularly strong drivers. Centralized models can introduce considerable delays and complexities in shipping sensitive biological materials and scheduling challenges when scaling production for individual patient batches. Decentralization aims to overcome these hurdles by bringing the manufacturing process closer to the patient.

Consequently, the very nature of the manufacturing technologies required is being redefined. There is an expanding demand for systems that are not only automated but also compact, user-friendly, and capable of operating reliably in diverse less-controlled environments than traditional pharmaceutical plants [7,8].

The success of these decentralized CGT models will be significantly influenced by the ability to navigate and overcome substantial regulatory challenges. A primary concern for regulatory bodies worldwide is ensuring consistent product quality, safety, and GMP compliance across a network of multiple, potentially non-traditional, manufacturing sites. The inherent variability introduced by different locations, potentially varied staff skill levels, and diverse operating environments poses a risk to maintaining uniform GMP standards. Therefore, technologies and the intellectual property that protects them will be exceptionally valuable, supporting

or guaranteeing consistency, sterility, and compliance in these distributed settings. The ability of an automated bioreactor system to guarantee or simplify GMP compliance across diverse sites becomes a major competitive differentiator. Solutions offering robust closed-system operation, advanced remote monitoring and control capabilities, and automated compliance documentation are becoming critical for gaining regulatory acceptance and, by extension, for the commercial viability and widespread adoption of decentralized CGT manufacturing models [4]. Successfully embedding these technologies within clinical workflows requires a crucial partnership between industry innovators and healthcare providers. A proven paradigm for this is the UK's Advanced Therapy Treatment Centres (ATTC) network, which brings together clinical/academic expertise to work with industry on developing the systems and processes needed for delivering CGT at the point of care. This collaborative model allows for the co-development of platforms that are not only technologically robust but also practical for use in real-world hospital environments. Such partnerships are essential for de-risking the adoption of new technology, establishing standardized operating and training protocols for clinical staff, and creating a scalable pathway for rolling out decentralized manufacturing from centers of excellence to the broader healthcare network.

Automated bioreactors: critical enablers for distributed production

Automated bioreactors have emerged as critical infrastructure in the decentralization of CGT manufacturing. These bioreactors are essential for ensuring that manufacturing is consistent, scalable, and compliant with GMP standards across different locations. They also reduce the need for manual work and make processes more reliable. These systems are rapidly evolving from tools primarily used in research or large-scale industrial production into pivotal components of GMP-compliant treatment delivery at or near the point of care. Automation directly addresses the core challenges posed by decentralization, such as maintaining stringent quality standards with potentially less specialized personnel at each site and ensuring process reproducibility across geographically dispersed locations.

The intellectual property landscape for these automated bioreactors is, therefore, becoming a crucial indicator of competitive positioning within the broader decentralized CGT manufacturing market. Dominance in bioreactor IP can translate directly into control over how these innovative therapies are produced in distributed settings. Companies that develop and patent the most effective, reliable, and GMP-compliant automated bioreactor platforms will provide the essential tools for this new manufacturing paradigm. Consequently, therapy developers and healthcare providers seeking to implement decentralized models will likely gravitate towards these leading platforms, granting significant market influence and share to the IP holders of these critical enabling technologies. The IP for these enabling platforms effectively makes their owners gatekeepers for therapy developers pursuing decentralized models.

Commercial examples of 'all-in-one' closed bioreactor solutions vividly illustrate this trend, embodying the 'GMP-in-a-box' concept. These systems are a direct response to the core challenges of distributed manufacturing. Systems such as Miltenyi Biotec's CliniMACS Prodigy® [9] and Lonza's Cocoon® Platform [10] are designed to automate multiple critical steps of the cell therapy manufacturing workflow—including cell isolation, genetic modification (transduction), expansion, and final harvest—all within a single, functionally closed system. These platforms are

specifically engineered for patient-scale production and are crucial for maintaining sterility and consistency, particularly in point-of-care or hospital-based settings. Such systems demonstrate how sophisticated automation and integration are being realized in commercial products tailored for the unique demands of decentralized manufacturing.

The pivotal role of intellectual property in shaping the market

In the dynamic and high-stakes field of automated bioreactors for CGT, intellectual property is far more than a mere mechanism for protecting inventions. It functions as a potent strategic tool that underpins market differentiation, secures competitive advantage, attracts substantial investment, and establishes critical strategic control points, such as platform lock-in and the defense of pricing power. The inherently high costs and profound complexity associated with CGT manufacturing processes significantly amplify the importance of automation and, consequently, the IP that protects these automated solutions. The substantial research and development investments required to bring these sophisticated systems to market necessitate robust IP protection to ensure a viable return on investment and to prevent rapid commoditization by competitors.

The nature of IP in this domain is undergoing a significant evolution. Historically, bioreactor IP might have focused on isolated hardware components, such as novel stirring mechanisms or vessel designs. However, as these systems become increasingly automated and integrated to meet the specific demands of CGT, the locus of value is shifting. Value is no longer found in just the individual components, but in how the hardware, software, analytics, and single-use parts all work together smoothly and in compliance with GMP standards. This shift is compelling companies to build comprehensive IP portfolios that cover this entire integrated ecosystem.

The result is the creation of complex 'Closed ecosystem' environments, a deliberate IP-driven business model where users become locked into a specific vendor's complete platform. Switching any part of such a validated, integrated system often becomes prohibitively difficult and costly, thereby solidifying the vendor's market position. This strategic utilization of IP has profound implications for market structure and innovation dynamics. It could potentially lead to significant market consolidation, where companies possessing the most comprehensive and defensible IP portfolios acquire smaller innovators [11] or compel competitors to operate within narrower, niche markets. Such consolidation, while potentially streamlining some aspects of technology development, might also impact the diversity of innovation and pricing structures in the long term. If a few large players come to dominate the landscape through strong IP control, it could influence which types of innovative approaches receive funding and development focus, and may affect the overall cost of these critical manufacturing technologies. This concentration of IP could stifle innovation across the industry. It risks limiting the variety of new technologies and may slow down progress in areas that large companies do not prioritize.

MAPPING INNOVATION & IP TRAJECTORIES IN AUTOMATED BIOREACTOR TECHNOLOGY

Global IP trends and growth dynamics

The field of automated bioreactors for CGT manufacturing is characterized by intense and sustained innovation, as evidenced by global intellectual property trends. Patent activity in this sector has demonstrated a notable upward trajectory, with a compound annual growth rate (CAGR) of

approximately 7.52% over the last 5 years. This robust growth rate underscores the significant and ongoing R&D investment and the dynamic nature of this technological space. It reflects a strong industry-wide emphasis on creating more efficient, scalable, and GMP-compliant automated solutions designed to meet the escalating demands of the rapidly expanding CGT industry.

The broader CGT biomanufacturing market itself is experiencing rapid expansion, substantially driven by these advancements in automation and the increasing integration of artificial intelligence (AI). This implies that AI and automation are not merely features but are acting as multiplicative forces, enabling further innovation across the bioreactor stack, and leading to more IP generation. Furthermore, the criticality of single-use technology in this domain is highlighted by the fact that over 400 patents related to single-use bioreactors (SUBs) have been filed or granted in recent years [12].

This sustained CAGR in patent filings suggests that despite the existence of established IP in the bioprocessing field, innovators continue to identify and pursue new avenues for patentable improvements. This ongoing innovation likely focuses on several key areas: incremental enhancements to existing platform technologies, the development of solutions tailored for new applications (such as bioreactors optimized for specific cell types critical to CGTs or systems uniquely suited for decentralized deployment), and the integration of emerging technologies like AI and advanced sensor systems. The continued dynamism indicates that the field is far from mature, with ample opportunities remaining for inventive contributions that can address unmet needs in CGT manufacturing. The sustained patent growth points towards niche specialization and continuous improvement, where innovation targets refining existing technologies for specific CGT requirements and solving previously unaddressed challenges in automation and single-use systems.

Geographical hotbeds of innovation: USA, Europe, and the ascendance of Asia

The geographical distribution of patent filings reveals a significant global race to innovate and secure market positions in automated bioprocessing, with a notable shift in the global innovation landscape. China has emerged as a dominant jurisdiction in terms of the sheer volume of patent filings related to automated bioreactors, with the USA following closely. This trend is further illuminated by recent data indicating China's rapidly advancing capabilities in broader biotechnology innovation. China now leads in the number of impactful biotech publications and has witnessed a dramatic surge in biotech Patent Cooperation Treaty (PCT) patent filings, which rose from a mere 119 in 2010 to 1,918 in 2023. This output surpasses that of Europe in most biotechnology areas and even the USA in some specific fields [13]. Notably, in 2023, China accounted for a 29% global share of the most-cited research papers in the field of biological manufacturing. This surge in high-quality research and international patent filings from China suggests a strategic move beyond mere patent volume towards generating impactful innovations that could lead to globally competitive products, a more significant competitive threat than volume alone.

Concurrently, South Korea is rapidly ascending as a significant biotech hub, propelled by strategic government initiatives such as the National Bio Committee and the National Synthetic Biology Initiative. The South Korean government has set ambitious targets, including achieving a US$149 billion biotech output by 2035 and substantially increasing the number of biotech venture firms. This proactive governmental

stance, a key differentiator in emerging innovation hubs, is attracting considerable investments from global bioprocessing players like Merck KGaA and Cytiva, alongside fostering the growth of innovative domestic firms such as Orum Therapeutics and Alteogen [14,15]. Furthermore, South Korea's market for single-use bioprocessing systems is experiencing robust growth, with a CAGR of 16.84% [16].

While Asian innovation is clearly on the rise, North America maintains a strong position, particularly in leading POC) cell and gene therapy manufacturing efforts and in the broader cell therapy raw materials market, where it held a 47% share in 2023 [4]. This leadership is underpinned by a robust R&D infrastructure, supportive regulatory frameworks from agencies like the US FDA, and significant ongoing investment. However, the Asia Pacific region, as a whole, is identified as the fastest-growing market, indicating a broadening and diversification of the global innovation landscape.

The UK has cultivated a leading global position in cell and gene therapy through a deliberate national strategy that integrates government, academia, and industry. A key strategic advantage is its agile regulatory environment; the Medicines and Healthcare products Regulatory Agency (MHRA) established the world's first comprehensive framework for decentralized and POC manufacturing, positioning the nation to lead this manufacturing paradigm shift. This forward-thinking approach, which includes the world-first approval of a CRISPR-based therapy, is underpinned by unique national assets like the CGT Catapult, an organization that bridges the gap between research and commercialization by providing critical manufacturing infrastructure and expertise.

This globalization of innovation, with emerging regional specializations, suggests that a purely US/EU-centric view of the IP landscape is no longer sufficient. The rise of these Asian innovation hubs is poised to introduce new competitive dynamics into the global automated bioreactor market, potentially leading to increased price pressures on established Western suppliers, and creating significant opportunities for cross-border collaborations, licensing agreements, and strategic partnerships. Furthermore, this trend may lead to a diversification of the global supply chain for critical bioprocessing technologies. Consequently, all stakeholders in the CGT manufacturing ecosystem must adopt global IP monitoring and filing strategies, as significant competition, valuable collaboration opportunities, and even new technological paradigms may increasingly arise from these rapidly advancing Asian regions. This globalization demands proactive global IP management from all players.

Key technological focus areas and patent categories

The innovation in automated bioreactors for CGT is multifaceted, with patent activity concentrated in several key technological domains. These categories reflect the critical needs of CGT manufacturing, from basic cell culture to complex, integrated processing and data management.

Core bioreactor hardware and novel designs (including 3D systems, perfusion)

Patents related to the core bioreactor hardware form a foundational layer of the IP landscape. This includes innovations in the bioreactor vessel itself, agitation mechanisms (e.g., stirred-tank, rocking motion), perfusion systems for continuous culture and high-density cell growth, and overall system configurations designed to optimize critical process parameters such as nutrient supply, gas exchange, pH, and temperature control.

Beyond conventional designs, there is a significant trend towards specialized

bioreactor architectures tailored for the unique requirements of different cell types and therapeutic applications. The specific needs of CGT, such as handling sensitive cells, developing 3D tissue structures, or achieving high-density immune cell cultures, are driving this diversification beyond traditional bioreactor designs and creating new IP niches. For instance, 3D bioreactor technologies, which aim to mimic the *in vivo* cellular microenvironment, are a focus for companies like Pluri Inc. (formerly Pluristem Therapeutics). Pluri has developed and patented systems for the 3D expansion of various cell types, including placental cells and immune cells like MAIT cells, often emphasizing the creation of lymph node-like conditions. United Therapeutics Corporation, with its focus on organ manufacturing, also holds IP likely covering specialized bioreactor systems for complex tissue and cell culture.

Perfusion systems are critical for achieving high cell densities and extended culture durations. Cytiva's Xcellerex™ Automated Perfusion System (APS) [17], Thermo Fisher Scientific's HyPerforma™ Single-Use Bioreactor (S.U.B.) with its patented crossflow sparger [18], and Sartorius's Ambr® and BIOSTAT® STR families all feature advanced perfusion capabilities [19]. Emerging companies are also contributing novel hardware designs. PBS Biotech is known for its Vertical-Wheel™ bioreactors for sensitive cells, and BioThrust is developing a 'bionic bioreactor' with a unique membrane architecture for bubble-free gas exchange, aimed at sensitive stem cell cultures.

A notable bifurcation in bioreactor technology development and associated IP strategies is evident. Traditional SSTRs remain the established standard for many applications, dominated by giants like Danaher (Cytiva, Pall), Sartorius Stedim Biotech, and Thermo Fisher Scientific. Innovation here centers on scalability, advanced single-use components, and PAT integration, often through incremental innovations building on extensive existing IP. In contrast, newer or more specialized companies such as Pluri Inc., PBS Biotech, and BioThrust are developing fundamentally novel bioreactor concepts, frequently tailored to specific CGT demands. This bifurcation creates a dynamic IP ecosystem where large players refine established platforms, while smaller innovators introduce disruptive specialized hardware, leading to potential M&A or licensing activities. The distinct IP landscapes—dense comprehensive web of patents for SSTRs versus newer IP for novel designs—will shape these interactions.

Single-use technologies: consumables and interfaces

Single-use technologies (SUTs) have revolutionized bioprocessing by eliminating cleaning and sterilization validation between batches, reducing turnaround times, and minimizing cross-contamination risks. Consequently, a significant volume of IP, with over 400 patents filed by various players [12], is dedicated to single-use bioreactor bags, tubing assemblies, impellers, sensors, aseptic connectors, and the overall integration of these disposable components. This is particularly critical for CGT, where closed and automated systems heavily rely on robust SUTs for sterility and reproducibility, especially for therapies like CAR-T cells.

The 'disposable kit interface' represents a major IP battleground. Companies that control the IP for critical single-use components can establish a business model based on recurring revenue and foster platform dependency. Leading bioprocessing companies like Danaher (Cytiva Xcellerex flow kits, Pall filtration), Sartorius Stedim Biotech (Flexsafe® bags, Biowelder® TC, Opta® SFT connectors), and Thermo Fisher Scientific (HyPerforma S.U.B. bags with BioTitan™ retention) have substantial IP in this area.

The IP strategy for SUTs is holistic, extending beyond the basic material of the disposable bag to encompass the entire integrated consumable assembly, including proprietary connector designs, specific impeller mechanisms, sensor integration methods, and defined fluid management pathways. This makes it exceptionally challenging for third-party manufacturers to offer compatible disposables, thereby reinforcing the user's reliance on the original vendor's platform. The defensibility of this model lies not just in the plastic material, but in the complex, patented design of the entire integrated assembly and its hardware interface.

Despite the maturity of the single-use paradigm, persistent challenges related to leachables and extractables, pre-use integrity of bags, and lack of standardization are fueling a 'second wave' [20] of innovation. This innovation focuses on enhanced robustness, improved material science, advanced sterility assurance mechanisms (like novel pre-sterilized connectors and reliable in-situ integrity testing methods), and broader applicability for CGT. These unresolved SUT challenges are active drivers for new IP opportunities. The lack of standardization, while a hurdle for users, is often a deliberate IP strategy by vendors. However, increasing regulatory or user pressure for interoperability could eventually lead to some standardization, potentially reshaping the current IP-driven competitive landscape.

Microfluidic systems and lab-on-a-chip bioreactors

Microfluidic bioreactors, or 'lab-on-a-chip' systems, represent an emerging and highly innovative frontier, enabling precise manipulation of extremely small fluid volumes for applications in research, process development, and potentially small-scale autologous therapies or POC manufacturing. Key principles include laminar flow, high surface-to-volume ratios enhancing mass transfer, and the ability to mimic *in vivo* microenvironments.

Intellectual property in this domain often originates from academic institutions and their spin-off companies, a distinct innovation pathway compared to incumbent-led SSTR development. Examples include Redbud Labs (microfluidic devices for cell processing) [21], Kytopen (an MIT spin-off with Flowfect® technology for non-viral gene delivery) [22], and others like Stilla Technologies and Fluid-Screen. Advantages include reduced reagent consumption, high-throughput screening, and enhanced microenvironment control, translating to potential scalability via parallelization and cost reduction for CGT.

However, scaling production volumes for therapies requiring very large cell numbers remains a key challenge, often involving massive parallelization of individual micro-reactors with their own complexities. This limitation shapes IP strategy, making it most impactful when focused on enabling technologies (like Kytopen's gene delivery platform) or niche applications (diagnostics, small-dose therapies) rather than direct competition with SSTRs for all large-scale cell expansion, unless significant IP breakthroughs overcome current scaling hurdles.

Software, automation, monitoring, and control (including AI/ML)

The 'intelligence' embedded within automated bioreactor systems—their software, automation capabilities, and sophisticated monitoring and control methods—is an increasingly critical area of IP concentration. This domain encompasses advanced sensor integration, real-time data analytics, PAT, automated feedback control, process orchestration, secure data management, cloud connectivity, remote GMP compliance, and the transformative applications of AI/ML for predictive control, anomaly detection, and real-time GMP assurance. The 'brains' of the bioreactor are becoming the primary value and IP driver.

Software control systems manage critical process parameters (CPPs), while data analytics convert raw data into actionable insights. PAT ensures final product quality through real-time monitoring and control. Established players and newer entrants are heavily investing in IP around these 'smart' system aspects:

- **Sartorius Stedim Biotech:** BioPAT® toolbox (sensors like Viamass, Xgas, Trace; software like SIMCA®, MODDE®, MFCS) [23]
- **Danaher (Cytiva):** integration of Rockwell's PlantPAx™ or Emerson's DeltaV™; Xcellerex APS with Wonderware™ [17]; Figurate™ automation platform
- **Thermo Fisher Scientific:** TruBio™ software with G3 Bioprocess Controllers; digital integration for CAR-T workflows [24]
- **Miltenyi Biotec:** CliniMACS Prodigy proprietary software for integrated workflows [9]
- **Ori Biotech:** IRO Platform with flexible, user-programmable software, remote HMI, and OriConnect™ for automated sterile fluid transfer [25,26]

AI/ML and digital twin technologies are rapidly advancing, with applications in optimizing perfusion rates, predicting batch success, detecting anomalies, and ensuring real-time GMP compliance [27]. However, AI/ML in bioprocessing faces a dual challenge: the complexity of IP protection for algorithms (often requiring demonstration of a concrete technical application rather than abstract concepts) and the need for rigorous regulatory validation of AI systems, especially those making autonomous GMP decisions. This necessitates strategies combining patents for specific technical implementations with trade secrets for core algorithms or datasets and drives innovation in explainable AI (XAI) to meet regulatory demands for transparency.

Integrated end-to-end cell processing platforms ('GMP-in-a-box')

A dominant trend, particularly for autologous therapies (e.g., CAR-T cells) and decentralized production, is the development of 'GMP-in-a-box' systems. These highly integrated platforms automate multiple, if not all, critical steps of the cell therapy manufacturing workflow within a single, functionally closed instrument. Intellectual property in this area is comprehensive, covering individual unit operations, their seamless integration, the overall system architecture, single-use fluidic pathways, and the orchestrating software. The IP value of these platforms lies critically in this patented integration, creating a powerful 'closed ecosystem'.

Several companies have established strong IP positions:

- **Lonza's Cocoon Platform:** automated, closed, flexible system for patient-scale manufacturing, integrating T-cell enrichment, activation, transduction, and expansion in a single-use cassette [10]
- **Miltenyi Biotec's CliniMACS Prodigy:** integrated solution for cell separation, cultivation, transduction, and formulation within a closed, single-use tubing set [28]
- **Cellares Corp's Cell Shuttle:** aims for true walk-away, end-to-end automation, integrating robotics and forming a core of their IDMO concept
- **Ori Biotech's IRO Platform:** designed to close, automate, and standardize CGT manufacturing, featuring the patented OriConnect system for automated sterile fluid transfer [25,26]

- **Terumo Blood and Cell Technologies:** offers the Quantum® Cell Expansion System and Finia® Fill and Finish System [10]

These platforms simplify CGT manufacturing complexities, reduce cleanroom footprints, minimize operator variability, and enable broader therapy adoption, especially in decentralized settings. The complex, multi-layered IP portfolios (a strategic collection of various intellectual property rights designed to protect an entire technology ecosystem rather than just a single invention) protecting these systems create strong vendor lock-in, significantly amplified by the substantial time and resources required for GMP process validation on a specific platform, making switching vendors prohibitively difficult. A strategic tension exists between developing highly optimized, locked-down systems for specific processes and the market demand for more flexible, adaptable platforms suitable for diverse cell types and protocols. IP that enables user-configurability and adaptability could become a key competitive differentiator.

COMPETITIVE LANDSCAPE: KEY PLAYERS, IP PORTFOLIOS, & NICHE DOMINANCE

The IP landscape for automated bioreactors in CGT is populated by a diverse mix of established bioprocessing giants, diversified life science companies, specialized CGT technology providers, emerging innovators, and academic institutions.

Leading patent assignees: profiles and strategic focus

Established bioprocessing giants and diversified life science companies

These companies typically leverage their extensive experience and broad IP portfolios in general bioprocessing to offer comprehensive solutions for CGT manufacturing. Their strengths often lie in robust, scalable platforms, well-characterized consumables, and strong regulatory support.

Key examples include:

- **Danaher Corporation (Cytiva, Pall Corporation):** a major force with wide-ranging patents in bioreactor design (Xuri™, ÄKTA™, Xcellerex), SUTs, automation, and Pall's critical filtration technologies

- **Sartorius Stedim Biotech:** a leading provider of bioreactors (BIOSTAT family, Ambr micro bioreactors), SUTs (Flexsafe bags), and PAT solutions (BioPAT toolbox)

- **Thermo Fisher Scientific:** significant IP in SUTs (HyPerforma S.U.B. series with patented sparger technology, BioTitan retention device), automation software (TruBio), and closed systems

- Lonza has established a formidable IP position with its Cocoon Platform, which exemplifies a 'multi-layered' IP strategy for controlling the integrated, patient-scale manufacturing workflow. This goes beyond protecting just the hardware. For example, patent WO2019046766A2 does not merely claim a device, but rather an entire automated method for producing genetically modified immune cells within a fully enclosed system. This broad process claim creates a significant 'Strategic control point' for competitors seeking to develop similar end-to-end automated CAR-T solutions. The 'layers' of Lonza's IP are further fortified by patents on the design of the proprietary single-use cassette and the software that controls the automated process, creating a deeply integrated and defensible 'closed ecosystem'

- **Miltenyi Biotec:** known for its CliniMACS Prodigy, holding substantial IP in closed-system cell separation, integrated bioreactor design, single-use tubing sets, and automation software. Other relevant players include Boehringer Ingelheim, Merck KGaA, WuXi AppTec, and Becton, Dickinson, and Company

These established players often pursue a strategy of providing validated, end-to-end solutions, frequently creating 'a comprehensive web of patents' (dense webs of overlapping patents covering foundational technologies and incremental improvements). This defensive IP strategy aims to protect substantial market shares and makes it challenging for new entrants to compete without infringement. Incumbents leverage these webs of patents as a primary defensive shield. Their primary challenge lies in maintaining agility against disruptive technologies from smaller firms, often leading them to rely on mergers and acquisitions (M&A) to acquire innovative startups and integrate next-generation technologies into their portfolios. M&A thus becomes a key strategy to counter agility deficits and access external IP.

Specialized CGT technology providers and emerging innovators

This category includes companies more narrowly focused on specific CGT challenges, often developing disruptive technologies or highly specialized solutions. Their IP portfolios typically center on novel bioreactor concepts, advanced automation, or unique cell processing approaches. Examples include:

- **Pluri Inc.:** known for 3D bioreactor technologies for placental and immune cell expansion
- **Athersys Inc.:** focuses on its MultiStem® allogeneic stem cell therapy platform with IP on scalable manufacturing
- **United Therapeutics Corporation:** involved in organ manufacturing, with IP in specialized bioreactors for complex tissue culture
- **Cellares Corp:** emerging leader with the Cell Shuttle platform, IP centered on robotics, end-to-end automation, and the IDMO model
- **Ori Biotech:** developing the IRO Platform, with IP including the OriConnect system and a flexible bioreactor design for decentralized manufacturing. Other companies like ImmunityBio, Inc., Chr. Hansen Holding A/S (microbial fermentation focus), and Weyerhaeuser Company (plant cell culture IP) also appear in patent landscapes, though their direct impact on human CGT bioreactor hardware may vary

These specialized innovators use IP as a 'spearhead' for market entry and differentiation. Their survival and growth depend heavily on the strength and enforceability of their foundational IP, which allows them to carve out unique, defensible market positions. The IP portfolio is a primary determinant of an emerging innovator's exit strategy (often M&A) or its potential growth trajectory; they are prime M&A targets for larger companies seeking cutting-edge technologies, with IP quality being key to their valuation.

Academic institutions and their spin-offs

Universities and their spin-offs are crucial incubators of novel technologies and foundational IP, particularly in cutting-edge areas like microfluidics, novel sensor development, and specialized bioreactor designs. Key academic institutions active in patenting include the University of New South Wales (UNSW), the University System of Maryland, and the Karlsruhe

Institute of Technology (KIT); Oxford University also has numerous spin-outs in related fields [29]. Academic IP often represents high-risk, high-reward foundational technology.

Spin-offs translate these innovations into marketable products:

- **Redbud Labs, Inc.:** focuses on microfluidic components and systems for cell manipulation
- **Kytopen (MIT spin-off):** developed the patented Flowfect technology, a microfluidics-based platform for non-viral cell engineering [22]
- **MaxCyte:** with its Flow Electroporation® technology, it has academic roots and is a key enabler in cell engineering. This academic-to-spin-off pipeline is a vital source of disruptive innovation. The terms of licensing agreements for this foundational IP between universities and spin-offs (and subsequently to larger companies) have long-term strategic consequences for the entire value chain, heavily influenced by the initial academic IP strength

Competitive clusters: dominance in specific technology niches

To clearly delineate organizational dominance in specific niches within the automated bioreactor landscape for CGT, Table 1 maps key patent assignees against critical technology categories [30,31]. The assessment of strength is based on company focus, product offerings, and explicitly mentioned IP strengths or patented features.

Established bioprocessing companies like Danaher, Sartorius, and Thermo Fisher demonstrate broad strengths across general hardware, SUTs, and PAT. Specialized platform providers such as Lonza and Miltenyi Biotec excel in integrated end-to-end systems. Newer entrants like Cellares and Ori Biotech are pushing boundaries in automation, robotics (notably Cellares), and flexible, closed systems. Academic spin-offs like Redbud Labs and Kytopen are key innovators in microfluidics, while Pluri Inc. shows strength in 3D bioreactor systems.

Competitive dominance in one technological niche often creates significant leverage in adjacent ones. For instance, a company holding strong IP in SUTs can strategically design its integrated bioreactor platform to be exclusively compatible with those SUTs, reinforcing its market position in both segments and enhancing platform lock-in. This interconnected IP strategy across multiple categories creates synergistic market control.

The emergence of 'Next-Generation Automation: Robotics and Highly Integrated, Flexible Platforms' as a distinct competitive cluster signifies a potential paradigm shift. IP in true robotics for cell handling (e.g., Cellares' 'IDMO Smart Factory' model or Cellular Origins' Constellation™ platform) [30], AI-driven operational flexibility, and industrial-scale automation concepts could prove disruptive if these platforms deliver markedly superior scalability, cost–effectiveness, or adaptability. This focus on robotics and industrial-scale automation represents a potential 'leapfrog' disruption over current integrated systems.

STRATEGIC IP CONTROL POINTS: ARCHITECTING MARKET LEADERSHIP AND PLATFORM INTEGRATION

Core bioreactor IP and the creation of 'closed ecosystem'

In the context of automated bioprocessing, a 'closed ecosystem' is a deliberate, IP-driven business strategy where a vendor creates a closed ecosystem consisting of a central instrument, proprietary software,

TABLE 1

Top patent holders by automated bioreactor technology category for CGT.

Technology category	Danaher (Cytiva, Pall)	Sartorius Stedim Biotech	Thermo Fisher Scientific	Lonza	Miltenyi Biotec	Pluri Inc.	Cellares Corp	Ori Biotech	Other key players (examples)
Novel bioreactor hardware (general)	High (Xcellerex™, Wave™)	High (BIOSTAT®, Ambr®)	High (HyPerforma™ S.U.B.)	Medium (Hardware for Cocoon®)	Medium (Hardware for CliniMACS Prodigy®)	Medium (specialized designs)	Medium (hardware for Cell Shuttle™)	Medium (IRO® hardware)	Athersys (scalable for MultiStem®), United Therapeutics (Organ mfg.), PBS Biotech (Vertical-Wheel™), BioThrust (Bionic)
3D Bioreactor systems	Medium (research focus)	Medium (research focus)	Medium (research focus)	Low/niche	Low/niche	High (patented 3D expansion)	Low/niche	Low/niche	
Perfusion systems	High (Xcellerex APS)	High (Integrated in BIOSTAT)	High (Capabilities in HyPerforma)	Medium (Cocoon capabilities)	Medium (Prodigy capabilities)	N/A	Medium (Cell Shuttle capabilities)	Medium (IRO capabilities)	
Single-use bioreactor bags and consumables (SUTs)	High (extensive portfolio, proprietary interfaces)	High (Flexsafe® bags, integrated consumables)	High (HyPerforma bags with BioTitan™, Aegis™/CX films)	High (Cocoon single-use cassettes)	High (Prodigy single-use tubing sets)	Medium (For 3D systems)	High (Consumables for Cell Shuttle)	High (Single consumable for IRO)	
Aseptic connectors and sterile fluid transfer	High (Pall Colder products, Cytiva components)	High (Opta® SFT, Biowelder® TC)	Medium (standard and custom solutions)	High (integrated in Cocoon cassettes)	High (integrated in Prodigy tubing sets)	Medium	High (integrated in Cell Shuttle)	High (OriConnect™ patented system)	
Microfluidic bioreactors/ lab-on-a-Chip	Low/niche (likely via partnerships/acquisitions)	Medium (Ambr leverages microscale, research tools)	Low/niche	Low/niche	Low/niche	Low/niche	Low/niche	Medium (conceptually, for precise control)	Redbud Labs (high), Kytopen (high—Flowfect®), academic spin-offs (emerging)
Sensors and monitoring (PAT)	High (integrated sensors, Cytiva Figurate™ automation)	High (BioPAT® toolbox: Viamass, Xgas, Trace, Fundalux)	High (integrated sensors, TruBio™ software compatibility)	Medium (sensors in Cocoon)	Medium (sensors in Prodigy)	Medium	Medium (sensors in Cell Shuttle)	Medium (integrated sensors in IRO)	Applikon (Getinge), Mettler Toledo
Automation software and control systems	High (Figurate, PlantPAx™, DeltaV™ integration)	High (BioPAT: SIMCA®, MODDE®, MFCS, Biobrain®)	High (TruBio™ software, G3 controllers)	High (Cocoon proprietary software)	High (CliniMACS Prodigy®software)	Medium	High (Cell Shuttle automation software)	High (IRO flexible software, HMI)	
AI/ML and predictive analytics in bioprocessing	Emerging (developing capabilities)	Medium (SIMCA® for MVDA, exploring AI)	Emerging (developing capabilities)	Emerging	Emerging	Low	Emerging (implied in 'Smart Factory')	Emerging (data analytics focus)	Specialized AI/software firms
Integrated end-to-end cell processing platforms	Medium (modular solutions, Cytiva Chronicle™)	Medium (modular approach, e.g., Ambr to BIOSTAT)	Medium (modular, e.g., CTS™ Rotea system and other modules)	High (Cocoon Platform)	High (CliniMACS Prodigy)	N/A (focus on expansion)	High (Cell Shuttle 'GMP-in-a-box')	High (IRO Platform 'end-to-end')	Terumo BCT (Quantum®, Finia®)
Robotics in cell manufacturing	Low/niche (automation, not full robotics focus)	Low/niche	Low/niche	Low/niche (automation within Cocoon)	Low/niche (automation within Prodigy)	N/A	High (core to Cell Shuttle platform)	Medium (automation)	Cellular Origins (Constellation™, academic research

Data from [30,31,32].

and essential, patented single-use consumables. The 'walls' of this ecosystem are built with intellectual property that makes the components functionally interdependent and incompatible with third-party products. This strategy creates 'platform lock-in', making it too expensive and difficult for users to switch away from a vendor's system once it has been validated. In the competitive field of automated bioreactors, companies use intellectual property as a key tool to control the market and make customers dependent on their platforms. Companies strategically concentrate IP filings around key aspects of the bioreactor 'stack'—hardware, software, sensors, and consumables—to create critical 'control points'. These control points are instrumental in developing 'closed ecosystem', where users become reliant on a specific vendor's proprietary and integrated platform, thereby defending the pricing power of these systems. This 'closed ecosystem' effect is a deliberate outcome of a multi-layered IP strategy.

Core areas for IP control include:

- **Closed system architecture:** IP covering novel single-use bag designs, aseptic connectors, sterile fluid transfer

Cell & Gene Therapy Insights 2025; 11(8), 867–896· DOI: 10.18609/cgti.2025.099

mechanisms, and integrated cell separation technologies are paramount for preventing contamination and ensuring GMP compliance

- **Sensor integration and automated feedback control:** patents on novel sensors for real-time CPP monitoring and the algorithms enabling automated feedback control allow companies to offer 'intelligent' bioreactors that optimize processes and reduce manual intervention

- **Single-use components and disposables:** a significant volume of IP is dedicated to proprietary single-use items, covering material compositions, design features, and integration methods

While beneficial for the IP holder, these 'closed ecosystem' can stifle broader innovation, limit interoperability, and potentially lead to higher costs for users. A powerful, non-IP factor that reinforces these IP-based lock-ins is the high cost and risk associated with GMP re-validation; once a process is validated on a specific platform, switching becomes a massive economic and regulatory deterrent.

Illustrations of strategic IP for foundational technologies

The establishment of 'strategic control point', meaning a type of intellectual property that gives a company control over an indispensable component, system module, or operational workflow within a broader technological process, through IP is a cornerstone of competitive strategy. By securing broad patents on entire operational workflows or indispensable system modules, companies can significantly influence the market, compelling competitors to license their technology or invest heavily in non-infringing alternatives, often confining them to narrower innovation corridors. These strategic control points are strategically chosen to control irreplaceable process steps or components.

Dominating workflows: end-to-end automated systems

Patents claiming entire automated manufacturing processes grant substantial market leverage. For example, WO2019046766A2, describes an automated method for producing genetically modified immune cells (e.g., CAR-T cells) in a fully enclosed system [33]. If upheld, such broad claims create a significant barrier for competitors aiming to develop similar comprehensive approaches. Similarly, US20130210130A1, detailing an automated cell culture arrangement with a closed cell culture module, covers a fundamental element in automated CGT, granting considerable control [34].

The 'Proprietary consumable model': IP in single-use connectors and components

This strategy, mirroring the 'printer and ink' model, involves designing hardware for exclusive compatibility with patented single-use components. The combination of IP on the consumable and the burden of GMP re-validation creates powerful user lock-in. Examples include:

- **CPC (Colder Products Company):** extensive portfolio of aseptic connectors (MPC™, MPX™, SaniQuik™) with patented design features ensuring sterility and ease of use [35–38]

- **Pall Corporation (Danaher/Cytiva) Kleenpak™ Connectors (e.g., US 8,454,059; US 7,959,192):** patented sterile connectors/disconnectors with features like a gendered design and peel-away strip, compelling reliance on Pall [39,40]

- **Sartorius Stedim Biotech Opta SFT Connectors:** patented ergonomic and

reliability-enhancing features for aseptic connections [41]

- **Cytiva ReadyMate™ Connectors (EP3803181A1):** a reusable connector member with proprietary disposable sterile cover portions, creating multi-layered lock-in [42]

Integrated hardware, software, and consumables ('closed ecosystem')

Companies construct comprehensive 'closed ecosystem' by securing IP over the entire integrated platform. as a prime example, integrating multiple cell processing steps with proprietary single-use tubing sets and control software [43–47].

Proprietary sensor integration: controlling data and process optimization

IP related to novel sensors and their seamless integration for real-time monitoring and automated feedback is a key strategic domain. Patents such as US10227555B2 (and related family) for 'composite sensor assemblies for single use bioreactors' and US11886176 for the 'bioreactor control system and method of use' [48–50]. These patents cover physical integration and signal processing, leading to physical, data/software, and process optimization dependency. Control over sensor technology and its data output is evolving into control over data ecosystems and future AI-driven optimization, creating a new layer of dependency.

Company IP strategies: defensive thickets, offensive maneuvers, and collaborations

Companies in the automated bioreactor space employ a range of IP strategies. A common approach, particularly among established players, is defensive patenting, creating 'web of patents'—dense webs of overlapping patents covering hardware, software, sensors, and SUTs to deter competitors and solidify market control. This mirrors the 'blockbuster drug' IP playbook, where companies like Genzyme (for agalsidase beta) and Roche (for Tocilizumab) built extensive patent estates around successful biologics and their associated production technologies [51–54], indicating that manufacturing platforms themselves are now viewed as high-value, defensible assets.

In response, competitors, especially new entrants, may utilize offensive IP strategies, such as 'IP leapfrogging' or designing around existing web of patents. Innovations in areas like continuous bioprocessing, novel SUT designs, or AI-optimized cell lines requiring unique bioreactor conditions can provide pathways to circumvent originator patents and establish new, defensible IP positions. This is a vital offensive strategy for challengers.

While core platform IP is often siloed, licensing, collaboration, and patent pools can occur for complementary technologies or to enable broader market access, similar to practices in other tech sectors and the broader life sciences [11,55,56]. Finally, there is an emerging trend of open-source hardware and software initiatives for bioreactors (e.g., minimalist bubble column bioreactors, the 'JANUS' 3D printable perfusion bioreactor), often from academic or DIY bio communities [57,58]. While not yet a significant commercial threat in GMP CGT, these initiatives could, in the long term, influence market expectations for cost and flexibility, potentially pressuring proprietary vendors to adapt.

The competitive dynamics described within this analysis, characterized by established incumbents refining complex systems versus agile entrants introducing novel platforms, closely mirror the classic theory of disruptive innovation articulated by Clayton Christensen. The large, established bioprocessing companies are engaged in sustaining innovation, incrementally improving their sophisticated

bioreactor platforms (like SSTRs) to serve the high-end demands of their existing customers. Their creation of 'closed ecosystem' ecosystems is a strategy to protect this profitable, high-margin market.

Conversely, disruptive innovations are emerging from newer, often smaller, companies focused on the specific needs of decentralization. Platforms like integrated 'GMP-in-a-box' systems or specialized microfluidic bioreactors may initially address niche or lower-margin applications, such as point-of-care manufacturing, that incumbents may overlook. However, as Christensen's model predicts, these disruptive technologies have the potential to 'move upmarket'. By simplifying complexity, reducing cost, and enabling manufacturing in entirely new settings, they could fundamentally restructure the industry. Over time, as these decentralized platforms mature and prove their scalability and reliability, they may challenge the dominance of the traditional, centralized manufacturing model, potentially displacing the very incumbents who once led the market. This dynamic suggests that the future industry structure will be shaped not just by incremental improvements but by the successful deployment of these disruptive, decentralized manufacturing technologies.

Strategic implications of IP control for market participants

The existence of potent IP control points carries significant strategic implications for all participants in the automated CGT manufacturing ecosystem.

For new entrants and smaller players, the dense IP landscape necessitates meticulous 'freedom to operate' (FTO) analysis before market entry. Strategies include designing around existing patents, innovating in narrower technological corridors, or seeking licenses.

For established players and incumbents, the focus is on reinforcing their 'closed ecosystem' through continuous IP filings, strategic acquisitions, and leveraging their IP portfolios to deter new entrants.

For all stakeholders, including therapy developers, CDMOs, and investors, a thorough understanding of the IP landscape is crucial when selecting an automation platform. Considerations must extend beyond technical specifications to include long-term consumable costs (the 'Proprietary consumable model'), vendor dependency, flexibility and switching costs (often prohibitively high post-validation), supply chain resilience, and interoperability (rare due to IP strategies). This means IP due diligence is no longer just for vendors but a critical strategic imperative for users and investors too, as platform choices have profound long-term lock-in and cost implications.

The competitive environment shows a clear trend: companies are strategically building IP portfolios around entire integrated systems and proprietary consumables. This creates an 'IP arms race' where the objective is to control the most comprehensive, user-friendly, and GMP-compliant ecosystem, shifting focus towards ecosystem control rather than just individual product protection. Success is increasingly intertwined with the strength, breadth, and strategic deployment of a company's IP portfolio covering these integrated solutions.

ENABLING DECENTRALIZATION: BIOREACTOR DESIGN & IP FOR DISTRIBUTED CGT MANUFACTURING

The strategic shift towards decentralized CGT manufacturing imposes unique demands on bioreactor systems, requiring them to be highly automated and meticulously designed for deployment in diverse, often space-constrained environments. IP in this domain increasingly focuses on features enhancing portability, ease of use,

interoperability, remote management, and overall system integration.

IP for compact, mobile, and integrated 'GMP-in-a-box' systems

A key IP thrust for decentralized applications centers on creating compact, mobile, and highly integrated 'GMP-in-a-box' solutions. Patents in this area cover:

- **Miniaturization and footprint reduction:** innovations consolidating multiple functionalities (cell separation, expansion, washing, harvesting) into smaller units, often involving novel layouts, microfluidics, and lightweight materials
- **Portability and robustness:** features facilitating easy transport, rapid setup, and maintenance of system integrity and sterility during movement (e.g., integrated carts, shock absorption)
- **Ease of use and reduced infrastructure demands:** systems minimizing specialized infrastructure needs (standard power, less cleanroom space via closed designs) and possessing intuitive user interfaces for less specialized personnel. IP that enables operation by personnel with less bioprocessing expertise, gains significant value as manufacturing moves to POC settings

Leading companies like Lonza (Cocoon Platform), Miltenyi Biotec (CliniMACS Prodigy), Cellares (Cell Shuttle), and Ori Biotech (IRO Platform) are developing platforms embodying these principles, often protecting these aspects through IP. The 'GMP-in-a-Box' concept extends beyond mere hardware miniaturization; it involves creating a self-contained, validated manufacturing environment. The IP protecting the *integration* of all necessary GMP functionalities (sterility assurance, monitoring, control, documentation) within that compact footprint is paramount. For decentralization, IP on system integration and ease of deployment is as critical as core process IP.

IP for plug-and-play interfaces, modularity, and system integration

For seamless decentralized workflows, bioreactors must integrate smoothly with other essential manufacturing modules (fill-finish, QC, cryopreservation). Consequently, IP is being generated around standardized connectors and interfaces, modular system integration, and automated data transfer.

- **Standardized connectors/interfaces:** development of universal aseptic connectors and data interfaces to allow bioreactors to 'plug into' downstream operations easily, enhancing sterility and efficiency
- **Modular system integration:** patents on architectural designs of modular platforms where unit operations can be flexibly combined and controlled as a cohesive system
- **Automated data transfer/process orchestration:** software IP for automated data handoff and overall process orchestration across integrated units

A fundamental tension exists, however, between the user-benefiting desire for 'plug-and-play' interoperability and the dominant 'Closed ecosystem' IP strategy of many vendors, which actively hinders true vendor-agnostic interoperability. IP for 'controlled interoperability', such as proprietary semi-open systems or specialized adaptors, may emerge as a pragmatic compromise, allowing vendors to maintain core control while offering some flexibility.

Software interoperability, cloud/edge monitoring, and remote compliance: IP considerations

Software and data management are pivotal for effectively managing distributed manufacturing networks and ensuring consistent quality and compliance. IP in this critical area includes:

- **Software interoperability and data standards:** developing software architectures and communication protocols (e.g., based on OPC UA) for secure data exchange and cohesive operation in distributed networks
- **Cloud-enabled remote batch monitoring and analytics:** systems for secure transmission of real-time batch data to a central cloud platform for remote monitoring, centralized data aggregation, and predictive analytics
- **Edge computing for localized intelligence and autonomy:** this is a crucial and rapidly emerging white space for IP. It involves performing advanced analytics and critical decision-making 'at the edge'—directly on or near the bioreactor system. This is vital for sites with limited connectivity or needing immediate autonomous adjustments without cloud latency. Local AI/ML algorithms can enable real-time decisions and adaptive control. IP protecting efficient edge AI algorithms, localized intelligent control, and robust offline operational capabilities are key to unlocking truly autonomous and robust decentralized operations
- **Remote GMP compliance and data integrity:** software platforms facilitating remote GMP enforcement (secure electronic batch records [EBRs], automated compliance documentation, remote audits). Robust cybersecurity measures and potentially blockchain for immutable audit trails are also areas for IP. Ensuring data integrity (e.g., FDA 21 CFR Part 11, EU Annex 11) is paramount. Cybersecurity and data integrity IP for distributed networks is non-negotiable for regulatory acceptance and commercial trust

WHITE SPACE ANALYSIS: UNTAPPED INNOVATION POTENTIAL IN AUTOMATED BIOREACTORS

While the IP landscape for automated bioreactors is increasingly populated, several domains present 'white space' opportunities for significant innovation (Table 2). To capitalize on these opportunities, innovators must not only create new technology but also ensure from the beginning that their designs align with regulatory standards, which is especially important for decentralized manufacturing.

Scrutinizing key white spaces

The following areas represent plausible white spaces or areas ripe for continued innovation:

Edge-compatible bioreactor software and analytics:

- **Opportunity:** sophisticated on-device software for advanced analytics, predictive maintenance, real-time anomaly detection, and adaptive control, enabling autonomous operation, especially with limited connectivity. This is vital for robust offline operation, reduced latency, and data security in distributed models
- **IP and feasibility:** identified as an under-patented 'white space [59,60]. While general AI patenting is up, specific bioreactor edge applications

TABLE 2

Detailed analysis of key white spaces in automated bioreactors for CGT.

White space area	Description and opportunity	Current IP density (rationale/evidence)	Key innovators/ potential players	Feasibility and challenges	Strategic importance for decentralized CGT
Edge-compatible bioreactor software and analytics	On-device advanced analytics, predictive maintenance, real-time anomaly detection, adaptive control for autonomous operation, limited connectivity	Low to medium; general AI patents rising, specific bioreactor edge applications less crowded; focus on technical application for patentability	Tech companies (IoT/edge AI), bioreactor manufacturers, startups	High feasibility; AI for real-time monitoring advancing; challenges: data standardization, integration, security, regulatory validation of AI	Critical; enables robust offline operation, reduced latency, data security, autonomous control in distributed/POC settings
Advanced automated CIP/SIP and SUT sterility assurance	Compact, automated CIP/SIP for reusables; advanced in situ integrity testing, novel materials/designs for superior SUT sterility assurance	Medium; general CIP/SIP and SUT sterility patents exist; novelty in full integration/automation for CGT or advanced verifiable SUT sterility	Bioreactor manufacturers., specialized cleaning tech companies, SUT suppliers, research institutions	Medium to high feasibility; automation key; challenges: CIP/SIP complexity for flexibles, cost of advanced SUT features, validation of novel sterility methods	High; ensures GMP compliance, economic viability for some reusables, patient safety, critical for less controlled decentralized environments
Real-time GMP assurance via AI (anomaly detection)	AI analyzing sensor/batch data to proactively ID deviations (contamination, malfunction, CQA drifts), predict compliance issues, suggest actions	Low to medium; general AI in QC/GMP emerging; specific, validated AI for predictive GMP in CGT bioprocessing is newer; patenting AI needs effect	AI/software companies, bioreactor manufacturers, Pharma companies (PAT), academia	High feasibility; AI tools exist; Challenges: data quality, model validation, explainability (XAI) for regulators, QMS integration	Very high; aligns with PAT/QbD; enhances product quality/consistency, reduces batch failures, streamlines compliance, enables release-by-exception
Microfluidic production systems for CGT	Precise, miniaturized, automated systems for small-scale autologous therapy mfg., PD, research	Medium (general microfluidics); low (full CGT production systems); dominated by academia/ startups in R&D	Startups, university spinouts, specialized microfluidics companies	Medium feasibility (niche production); challenges: scaling (larger doses), cell handling (shear, clogging), integration, chip CoGs	High for POC/personalized medicine; potential for cost reduction, faster turnaround (autologous), new research models
Modular 'factory-in-a-box' platforms	Integrated, automated, closed systems combining multiple CGT mfg. steps into a compact, deployable unit	Medium to high; several companies have platforms (Lonza, Miltenyi, Cellares, Ori) with IP on integration and automation	Established cell therapy platform providers, new entrants (full automation)	High feasibility (prototypes exist/ commercializing); challenges: true 'plug-and-play' interoperability, cost, validation of complex integrated systems	Critical for decentralization; simplifies deployment, standardizes processes across sites, reduces facility needs

Source data from [32]

are less crowded. Patentability hinges on demonstrating concrete technical application improving system efficiency or enabling new functionalities. Feasibility is high due to advancing AI and real-time monitoring

- **Players:** tech companies (IoT/Edge AI), bioreactor manufacturers, startups. The patentability challenge underscores the need for IP strategies focusing on the technical application of AI to solve specific bioreactor problems

Advanced automated CIP/SIP and SUT sterility assurance:

- **Opportunity:** for reusables, compact, efficient, fully automated cleaning-in-place (CIP)/sterilization-in-place (SIP) modules [61]. For SUTs, advanced pre-sterilized, pre-assembled, easily verifiable closed systems with enhanced, rapid, reliable *in situ* integrity testing methods
- **IP and feasibility:** medium IP density for automated CIP/SIP in POC/allogeneic applications; high for hub-spoke scalability. General CIP/SIP and SUT sterility patents exist, but novelty lies in full integration/automation for CGT or next-gen verifiable SUT sterility. Automation is a strong trend
- **Players:** bioreactor manufacturers, specialized cleaning tech companies, SUT component suppliers, research institutions. The key SUT white space is verifiable and automated *in situ* integrity testing

Real-time GMP assurance via AI-based anomaly detection and predictive compliance:

- **Opportunity:** AI analyzing complex, multi-parametric data in real-time to proactively identify subtle deviations and predict potential GMP compliance issues (contamination, equipment malfunction, CQA drifts) before they escalate. This aligns with PAT and QbD frameworks
- **IP and feasibility:** low to medium IP density. Specific AI applications for predictive GMP in CGT biomanufacturing is an emerging field. Feasibility is high, with AI explored for predictive QA. Explainability (XAI) is critical for regulatory acceptance
- **Players:** AI/software companies, bioreactor manufacturers, pharma companies developing PAT, academia. 'Predictive compliance' offers transformative potential, moving beyond reactive control to intelligent manufacturing. IP for XAI methods applied to GMP bioprocessing is also a valuable sub-white space

Microfluidic production systems for CGT:

- **Opportunity:** precise, miniaturized, automated systems for small-scale autologous therapy manufacturing, process development, or research. Potential for cost reduction and enabling POC deployment
- **IP and feasibility:** medium IP density in general microfluidics (often academia/startups); lower for full CGT *production* systems. Feasibility for niche production is medium; scaling for larger doses and GMP compliance at microscale are challenges
- **Players:** startups, university spinouts, specialized microfluidics companies. The primary white space lies in the integration and automation of multiple CGT processing steps onto a single, robust, GMP-compliant microfluidic production platform

Modular 'factory-in-a-box' platforms

- **Opportunity:** integrated, automated, closed systems combining multiple CGT manufacturing steps into a compact, deployable unit, simplifying deployment and standardizing processes for decentralization
- **IP and feasibility:** medium to high IP density, with companies like Lonza, Miltenyi, Cellares, and Ori having

platforms with IP around integration and automation. Feasibility is high (systems exist/commercializing)

- **Players:** established cell therapy platform providers, new entrants focusing on full automation. The white space may lie in achieving true flexibility and adaptability within a standardized platform architecture, enabling one platform to handle diverse therapies

Next-generation single-use sensors and analytics

- **Opportunity:** improved single-use, robust, reliable, multi-parameter sensors seamlessly integrated into SUTs, providing real-time data on a wider range of CPPs and CQAs. Integration with AI/ML for enhanced real-time monitoring and predictive control

- **IP and feasibility:** ongoing drive for improvement despite existing sensor IP. Better real-time data is fundamental for PAT, QbD, and AI-driven insights

- **Players:** sensor technology companies, bioreactor manufacturers, SUT suppliers, research institutions. The white space includes sensor fusion and data analytics at the sensor level

The analysis of these white spaces reveals a significant overarching trend: the increasing importance of 'software-defined biomanufacturing'. Many identified opportunities point towards a future where software, data management, and AI are as critical to a bioreactor system's value and performance as its physical hardware. Consequently, IP in these digital domains will likely become a key differentiator. Another key area of evolution lies in the definition and assurance of 'sterility', with innovation moving towards advanced, verifiable methods of ensuring system integrity and closure, especially for SUTs, and truly automated, verifiable CIP/SIP for reusables.

Aligning innovation with evolving regulatory frameworks

Innovations in automated bioreactors, particularly those targeting white spaces, must be developed with keen awareness of and alignment with evolving global regulatory standards (e.g., from FDA, EMA, MHRA). This is crucial for successful market translation, especially for decentralized CGT.

Regulatory considerations are paramount for:

- **Edge AI and analytics:** systems must ensure data integrity (e.g., FDA 21 CFR Part 11), security (HIPAA, GDPR), and traceability, even in distributed models

- **Automated CIP/SIP and SUT sterility:** reusables must meet stringent sterility and cleaning validation. SUTs require superior sterility assurance (e.g., aligning with EU Annex 1)

- **AI for GMP assurance:** AI systems need thorough validation, explainability for regulators, and data integrity, aligning with PAT and QbD frameworks

There is an opportunity for 'regulatory IP'—innovations and patents specifically addressing or simplifying compliance. Proactive engagement with regulatory agencies during development (e.g., FDA INTERACT meetings, EMA innovation task force consultations) can de-risk innovation and provide a first-mover advantage.

TRANSLATING IP INSIGHTS INTO BUSINESS OPPORTUNITIES & STRATEGIC IMPERATIVES

Successfully navigating the complex IP landscape demands connecting innovations to tangible business opportunities by

solving critical industry problems, improving manufacturing efficiency and compliance, and enhancing patient outcomes.

IP strategies for capitalizing on white space opportunities

Tailored IP strategies are essential for each white space:

- **Edge-compatible software/analytics:** hybrid IP (patents for technical solutions, trade secrets for algorithms/datasets) to establish indispensable edge capabilities
- **Automated CIP/SIP and SUT sterility:** patent novel integrated module designs, cleaning methods, verification sensors for CIP/SIP. For SUTs, patent advanced *in situ* integrity tests, novel materials, verifiable closed system designs, and aseptic connectors
- **AI for real-time GMP assurance:** patent AI algorithms for detecting GMP deviations and systems for automated alerts/actions or batch record review. Demonstrating technical effect is key
- **Microfluidic production systems:** patent novel chip architectures, microfabrication techniques, precise cell manipulation/culture methods, and integrated sensing/actuation for CGT
- **Modular 'factory-in-a-box' platforms:** secure broad IP on overall system architecture, integration methods, fluidic pathways, and orchestrating software
- **Improved single-use sensors/analytics:** patent novel sensor materials, modalities, multi-parameter sensing, and sterile/robust SUT integration. A 'one-size-fits-all' patenting strategy is insufficient; hybrid approaches combining patents with trade secrets are increasingly important, especially for software and AI

Articulating commercial potential: market sizing and impact

The commercial value of IP-protected innovations stems from addressing critical CGT manufacturing challenges, such as automating QC to reduce labor and variability, or advanced SUT integrity testing to reduce contamination risk [62–64].

The market context is compelling:

- Global CGT market: US$18.13 billion in 2023, projected to US$97.33 billion by 2033 (CAGR 18.3%) [65]
- CGT tools and reagents market: US$10.0 billion in 2024 to US$16.7 billion by 2029 (CAGR 10.8%) [65]
- Cell therapy manufacturing market: US$4.90 billion (current year) to US$13.83 billion by 2035 (CAGR 9.90%) [66]
- Single-use bioreactors market: projected to US$10.42 billion by 2034 (CAGR 9.0%) [67], with some estimates suggesting ~17% CAGR through 2035. Capturing even a modest share [1] of this booming multi-billion dollar market offers significant returns. For example, an IP-protected AI solution for predictive compliance in decentralized CAR-T manufacturing (T-cell therapies projected >45% of clinical demand by 2035) [68] could capture substantial revenue

Broader benefits amplify value:

- **Faster turnaround times:** automation reduces vein-to-vein time, critical for aggressive diseases [69]

- **Lower cost per therapy:** efficiency gains can reduce high CGT costs, improving accessibility [70]
- **Improved therapy success rates and safety:** enhanced process control and sterility lead to higher quality, safer, more efficacious therapies [71]
- **Enhanced patient access through decentralization:** 'factory-in-a-box' systems simplify logistics and improve access [72]. Articulating this human impact alongside financial projections strengthens the business case for IP-protected innovation

Strategic recommendations for innovators and investors

To thrive, proactive and informed strategies are needed.

For innovators (technology developers, bioreactor manufacturers):

- **Focus on validated white spaces:** prioritize R&D and IP in areas like edge AI, advanced automation in sterility assurance, and AI for real-time GMP compliance
- **Adopt hybrid IP for software/AI:** combine patents for technical applications with trade secrets for core algorithms and datasets [73]
- **Design for modularity/interoperability (with IP considerations):** develop IP supporting modular designs and standardized interfaces where feasible for decentralization, while strategically protecting proprietary interfaces for critical consumables/software to create lock-in
- **Invest heavily in data systems/software IP:** protect innovations in software, AI, cloud/edge computing enabling robust remote control, monitoring, analytics, and secure data management [74,75]
- **Prioritize regulatory adaptability:** design systems and file patents with global regulatory trends (PAT, QbD, real-time release, electronic records) in mind
- **Consider full lifecycle IP:** extend protection beyond the bioreactor to integrated QC, fill-finish, logistics, and data management [62,76]
- **Monitor global IP landscape:** track activity from emerging hubs (e.g., China, South Korea) [2,3,13–16]

For investors (venture capital, private equity, corporate venture):

- **Scrutinize IP portfolios:** conduct thorough due diligence on patent strength, breadth, defensibility, FTO, and blocking IP
- **Target companies in validated white spaces:** focus on innovations with significant market potential and strong IP strategy
- **Evaluate ecosystem control potential:** assess if IP strategy can lead to significant control (proprietary consumables, software platforms, integrated systems), indicating market power and M&A attractiveness [11]
- **Assess regulatory astuteness:** favor companies whose innovations facilitate compliance
- **Look for global IP awareness:** invest in companies with global IP strategies

CONCLUSION: ALIGNING IP STRATEGY WITH PLATFORM DEPLOYMENT & MARKET REALITIES

The journey towards effective, widespread decentralized cell and gene therapy manufacturing is inextricably linked to continued advancements in automated bioreactor technology and the strategic deployment of intellectual property. These sophisticated systems are fundamental to achieving the consistency, scalability, GMP compliance, and cost–effectiveness demanded by distributed production models.

The IP landscape surrounding these automated bioreactors is dynamic, fiercely competitive, and increasingly global. Key players are establishing strategic control points around closed-system architectures, advanced sensor integration, proprietary single-use consumables, and critically, sophisticated software, data management, and AI solutions. This strategic patenting aims to create 'closed ecosystems', ensuring platform lock-in and defending pricing power.

Key findings from this analysis indicate a shifting geography of innovation, with Asia (particularly China and South Korea) emerging as a significant force. Distinct technological clusters are solidifying, with established giants refining SSTRs while startups and academia drive microfluidic and novel reactor designs for niche applications. While SUT principles are mature, innovation persists in advanced sterility assurance and integrity verification. Crucially, significant 'white space' opportunities persist, especially at the intersection of bioprocessing and digital technologies: edge-compatible software and analytics, AI-driven real-time GMP assurance, and advanced data management for decentralized networks.

To capitalize on these opportunities, a proactive, forward-thinking IP strategy is essential, intrinsically linked to a company's platform deployment model and the tangible market needs it aims to address. The value of IP is magnified when it solves critical problems related to CGT cost, scale, quality, and accessibility. For innovators, this means aggressively patenting in white spaces, employing hybrid IP approaches for software/AI, focusing on modularity while strategically protecting proprietary interfaces, and designing for regulatory adaptability. For investors, it requires diligent scrutiny of IP portfolios for defensible control points, FTO, and a clear link between innovation and significant business opportunity within the multi-billion dollar CGT market [1,65–68].

Looking ahead, while proprietary systems currently dominate, the potential for increased collaboration or open standards for foundational technologies could emerge. However, the prevailing trend suggests that companies successfully navigating and shaping the IP landscape for automated bioreactors—those securing and leveraging IP to control scalability, quality, compliance, and data at the manufacturing edge—will be best positioned to lead. A well-crafted IP strategy, aligned with technological innovation, market realities, and regulatory foresight, is paramount in realizing the full potential of decentralized CGTs for patients worldwide.

REFERENCES

1. Single use bioreactors market industry trends and global forecasts to 2035: over 400 patents filed for single-use bioreactors, reflecting growing industry innovation. *Businesswire* Apr 21, 2025. https://www.businesswire.com/news/home/20250421656903/en/Single-Use-Bioreactors-Market-Industry-Trends-and-Global-Forecasts-to-2035-Over-400-Patents-Filed-for-Single-Use-Bioreactors-Reflecting-Growing-Industry-Innovation---ResearchAndMarkets.com.
2. China National Intellectual Property Administration. IP boosts bio-economy development in China. Jun 22, 2022. https://english.cnipa.gov.cn/art/2022/6/22/art_2829_176141.html#:~:text=China%20National%20Intellectual%20Property%20Administration,Bio%2DEconomy%20Development%20in%20China&text=Bio%2Deconomy%20is%20a%20new,part%20of%20the%20national%20economy.
3. Intellectual Technology & Innovation Foundation. How innovative is China in biotechnology? Jul 30, 2024. https://itif.org/publications/2024/07/30/how-innovative-is-china-in-biotechnology.
4. Businesswire. Point-of-care cell and gene therapy manufacturing market report 2025–2035. Closed system bioreactors and AI-bioprocessing set to shape PoC manufacturing by 2035. Apr 2, 2025. https://www.businesswire.com/news/home/20250402936461/en/Point-of-Care-Cell-and-Gene-Therapy-Manufacturing-Market-Report-2025-2035---Closed-System-Bioreactors-and-AI-Bioprocessing-Set-to-Shape-PoC-Manufacturing-by-2035---ResearchAndMarkets.com.
5. Harrison RP, Ruck S, Medcalf N, *et al.* Decentralized manufacturing of cell and gene therapies: overcoming challenges and identifying opportunities. *Cytotherapy* 2017; 19(10), 1140–1151.
6. Ganeeva I, Zmievskaya E, Valiullina A, *et al.* Recent advances in the development of bioreactors for manufacturing of adoptive cell immunotherapies. *Bioengineering (Basel)* 2022; 9(12), 808.
7. Harrison RP, Ruck S, Rafiq QA, *et al.* Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors. *Biotechnol. Adv.* 2018; 36(2), 345–357.
8. Melocchi A, Schmittlein B, Sadhu S, *et al.* Automated manufacturing of cell therapies. *J. Control. Rel.* 2025; 381, 113561.
9. Miltenyi Biotec USA CliniMACS Prodigy®. https://www.miltenyibiotec.com/US-en/products/clinimacs-prodigy.html.
10. ISCT 2025 New Orleans partners. https://www.isctglobal.org/annual-meeting/sponsors-partners/partners.
11. Ropes & Gray guides up to $10.1 billion in life sciences licensing and M&A deals over two weeks. *Ropes & Gray LLP* Mar 28, 2025. https://www.ropesgray.com/en/news-and-events/news/2025/03/ropes-gray-guides-life-sciences-licensing--ma-deals-over-two-weeks.
12. Businesswire. Single use bioreactors market industry trends and global forecasts to 2035: Over 400 patents filed for single-use bioreactors, reflecting growing industry innovation. Apr 21, 2025. https://www.businesswire.com/news/home/20250421656903/en/Single-Use-Bioreactors-Market-Industry-Trends-and-Global-Forecasts-to-2035-Over-400-Patents-Filed-for-Single-Use-Bioreactors-Reflecting-Growing-Industry-Innovation---ResearchAndMarkets.com.
13. Brown A, Groenewegen-Lau J. Lab leader, market ascender: China's rise in biotechnology. *Merics* Apr 24, 2025. https://merics.org/en/report/lab-leader-market-ascender-chinas-rise-biotechnology.
14. Son SJ. Digital healthcare patent applications grow in South Korea. *ManagingIP* Sep 23, 2021. https://www.managingip.com/article/2a5bqtj8ume32iwlaoy01/digital-healthcare-patent-applications-grow-in-south-korea.
15. Siddiqui A. The rise of K-Biotech. *BioSpectrum Asia* May 1, 2025. https://www.biospectrumasia.com/analysis/26/25968/the-rise-of-k-biotech.html.

16. Credence Research. *South Korea Single-Use Bio-Processing Systems Market.* May 17, 2025. https://www.credenceresearch.com/report/south-korea-single-use-bio-processing-systems-market.

17. Cytiva. Xcellerex™ X-platform cell culture bioreactors. https://www.cytivalifesciences.com/en/us/solutions/bioprocessing/products-and-solutions/upstream-bioprocessing/single-use-bioreactors/xcellerex-x-platform-bioreactors.

18. Thermo Fisher Scientific. HyPerforma Single-Use Bioreactor. https://www.thermofisher.com/na/en/home/life-science/bioproduction/single-use-bioprocessing/single-use-equipment/single-use-bioreactors/open-architecture-single-use-bioreactors.html.html.

19. Sartorius. Single-Use Bioreactors. https://www.sartorius.com/en/products/fermentation-bioreactors/single-use-bioreactors.

20. Eissal A. Single-use in the biopharmaceutical industry: a review of current technology impact, challenges and limitations. *Food Bioprod. Process*. 2013; 93, 57–72.

21. Beebe DJ. Enhancing epigenetic analysis of rare cells with multi-phase microfluidics. *NIH RePORTER* Jan 31, 2024. https://reporter.nih.gov/project-details/10775716.

22. Kytopen. Kytopen reveals automated high-throughput gene editing platform to accelerate cell therapy discovery, development, and manufacturing. May 24, 2023. https://www.kytopen.com/news/kytopen-reveals-automated-high-throughput-gene-editing-platform-to-accelerate-cell-therapy-discovery-development-and-manufacturing.

23. Sartorius. Process Analyzers Toolbox. https://www.sartorius.com/en/products/process-analytical-technology/sensors-analyzers/biopat/toolbox.

24. Thermo Fisher Scientific. Closed system automation for cell therapy. Feb 15, 2023. https://www.thermofisher.com/blog/behindthebench/closed-system-automation-cell-therapy.

25. Ori Biotech: Products, Competitors, Financials, Employees, Headquarters Locations. CB Insights. https://www.cbinsights.com/company/ori-biotech.

26. Oribiotech. IRO®. https://oribiotech.com/iro.

27. Fierce Pharma. Accelerating biomanufacturing through integrated digital twin technologies. May 12, 2025. https://www.fiercepharma.com/sponsored/accelerating-biomanufacturing-through-integrated-digital-twin-technologies.

28. Melocchi A, Schmittlein B, Jones AL, *et al*. Development of a robotic cluster for automated and scalable cell therapy manufacturing. *Cytotherapy* 2024; 26(9), 1095–1104.

29. The Department of Engineering Science, University of Oxford. Spinout companies. https://eng.ox.ac.uk/about/spinout-companies.

30. News Medical. Cellular Origins launches constellation, its configurable robotic platform to enable scalable manufacture of advanced therapies. May 31, 2023. https://www.news-medical.net/news/20230531/Cellular-Origins-Launches-Constellation-its-Configurable-Robotic-Platform-to-Enable-Scalable-Manufacture-of-Advanced-Therapies.aspx.

31. Cellular Origins. Cellular Origins acquires ACTIA Platform IP to enhance automated cell therapy manufacturing. Jul 2, 2024. https://cellularorigins.com/resource/cellular-origins-acquires-actia-platform-ip-to-enhance-automated-cell-therapy-manufacturing.

32. PatentVest. PatentVest IP Intelligence System. (Proprietary data platform). https://www.patentvest.com/

33. World Intellectual Property Organization. WO2019046766A2. End-to-end cell therapy automation. Mar 7, 2019. https://patents.google.com/patent/WO2019046766A2/en.

34. United States Patent Application Publication. US20130210130A1. Automated cell culture system. Aug 15, 2013. https://patents.google.com/patent/US20130210130A1/en.

35. CPC. Aseptic connectors for cell culture. https://www.cpcworldwide.com/Biopharma/Upstream/Cell-Culture.

36. CPC. MPC/MPX back-to-back series adapters spec sheets. https://pim-resources.coleparmer.com/data-sheet/cpc-mpc-mpx-back-to-back-spec-sheet.pdf.

37. SANIQUIK™. https://www.avintos.ch/fileadmin/user_upload/Homepage%202018/10_Produkte/04_Schnellkupplungen/Medien/KUP_CPC_DAT_SANIQUIK_EN.pdf.

38. CPC .Trademark and patent statements. https://www.cpcworldwide.com/Knowledge-Center/Trademarks-Patents.

39. Pall. Sterile connectors and disconnectors. https://shop.pall.com/us/en/products/sterile-connectors;sid=rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr.

40. Pall. Patents. https://www.pall.com/kr/ko/about-pall/patents.html.

41. Sartorius. Opta® SFT sterile connector. https://shop.sartorius.com/us/p/opta-sft-sterile-connector/opta-sft-sterile-connector.

42. European Patent Office. EP3803181A1. Connector for aseptic connection, and method for connecting and disconnecting such connectors. https://patents.google.com/patent/EP3803181A1/en.

43. Miltenyi Biotech. The CliniMACS Prodigy® platform. https://www.winmed.com/storage/content/our-business/medical-production/cell-molecular/cell-therapy/brochure/clinimacs-prodigy-system-flyer.pdf.

44. Biocompare. CliniMACS Prodigy automated cell manufacturing platform from Miltenyi Biotec. https://www.biocompare.com/24500-Cell-Sorters-Cell-Sorting-Instruments/22872931-CliniMACS-Prodigy-174/.

45. Miltenyi Biotec. Key features of the CliniMACS Prodigy tubing sets. https://www.miltenyibiotec.com/US-en/products/cell-manufacturing-platform/clinimacs-prodigy-platform/key-features-of-the-clinimacs-prodigy-tubing-sets.html.

46. Miltenyi Biotec. Mesenchymal stem cell expansion. https://www.miltenyibiotec.com/DE-en/applications/mesenchymal-stem-cells/mesenchymal-stem-cell-expansion-in-a-gmp-compliant-closed-and-automated-system.html.

47. Miltenyi Biotec. CliniMACS Prodigy principle. https://www.miltenyibiotec.com/US-en/products/cell-manufacturing-platform/clinimacs-prodigy-platform/CliniMACS-Prodigy-principle.html.

48. PatentGuru. Finesse Solutions, Inc. Patents. https://www.patentguru.com/assignee/finesse-solutions-inc?page=4.

49. PatentsJustia. Patents assigned to Finesse Solutions, Inc. https://patents.justia.com/assignee/finesse-solutions-inc.

50. European Patent Office. EP2503320B1. Composite sensor assemblies for single-use bioreactors. https://patents.google.com/patent/EP2503320B1/en.

51. PatentPC. How to navigate the biopharmaceutical patent thicket. Jul 23, 2025. https://patentpc.com/blog/navigate-the-biopharmaceutical-patent-thicket#:~:text=Navigating%20this%20patent%20thicket%20is,the%20scientific%20and%20legal%20landscapes.

52. PatSnap Synapse. The patent landscape of agalsidase beta. Mar 17, 2025. https://synapse.patsnap.com/article/the-patent-landscape-of-agalsidase-beta.

53. PatSnap Synapse. Roche vs Biogen: the tocilizumab patent battle. Apr 25, 2025. https://synapse.patsnap.com/blog/roche-vs-biogen-the-tocilizumab-patent-battle-a-brand-name-drug-defense-in-the-era-of-biosimilars.

54. DrugPatentWatch. Revolutionizing the fight against biologic drug patent thickets. May 19, 2025. https://www.drugpatentwatch.com/blog/revolutionizing-the-fight-against-biologic-drug-patent-thickets/?srsltid=AfmBOooq2JWXWU-iZZDY4_tAhBV-KdJAE9kRHbGdRhSrl4iNGrhunMCF.

55. Tran B. The role of patent pools in commercialization. *PatentPC* Jul 21, 2025. https://patentpc.com/blog/the-role-of-patent-pools-in-commercialization#:~:text=By%20allowing%20multiple%20patent%20holders,accelerate%20the%20deployment%20of%20innovations.

56. Shorthose S. Licensing and collaborations in life sciences. *Bird & Bird* Oct 28, 2024. https://www.twobirds.com/en/insights/2024/global/licensing-and-collaborations-in-life-sciences.

57. Gandia A, Christiansen S. Low-cost DIY bioreactor system for educational and research applications: an accessible off-the-shelf bubble column concept. *bioRxiv* 2025; published online Apr 21. https://www.biorxiv.org/content/early/2025/04/21/2025.04.21.649716.57.

58. Meneses J, Fernandes SR, Silva JC, *et al.* JANUS: an open-source 3D printable perfusion bioreactor and numerical model-based design strategy for tissue engineering. *Front. Bioeng. Biotechnol.* 2023; 11, 1308096.

59. IP. 2025 patent trends: challenges and innovations shaping the future of technology. Dec 10, 2024. https://ip.com/blog/2025-patent-trends-challenges-and-innovations-shaping-the-future-of-technology.

60. Tran B. Edge computing patents: overcoming eligibility issues in cloud infrastructure. *PatentPC* Jul 14, 2025. https://patentpc.com/blog/edge-computing-patents-overcoming-eligibility-issues-in-cloud-infrastructure.

61. Wiencek M. A risk-based approach to clean-in-place (CIP) cycle development. 2006; International Society for Pharmaceutical Engineering (reprint from *Pharm. Eng.* 2006; 26).

62. Aguiar T. Is early automation the key to scalable cell therapy manufacturing? *Cell & Gene* May 8, 2025. https://www.cellandgene.com/doc/is-early-automation-the-key-to-scalable-cell-therapy-manufacturing-0001.

63. Chatterjee B, Follstad B, Schirmer E, *et al.* Disposables/single use roundtable. *American Pharmaceutical Review* Oct 31, 2019. https://www.americanpharmaceuticalreview.com/Featured-Articles/359693-Disposables-Single-Use-Roundtable.

64. Playter G. Weighing the benefits of single-use consumables. *BioPharm Int.* 2024; 36(7), 36–39.

65. BCC Research. Global market for cell and gene therapy market. Jan 7, 2025. https://www.bccresearch.com/pressroom/bio/global-market-for-cell-and-gene-therapy-market?srsltid=AfmBOopSdoxoxQEwigMsuL0-cE2OobDmoWjlaQGdoB7k5w631yCD1a_B.

66. GlobeNewswire. Cell therapy manufacturing market expected to triple by 2035: analysis of growth opportunities in emerging therapies. Apr 4, 2025. https://www.globenewswire.com/news-release/2025/04/04/3055746/28124/en/Cell-Therapy-Manufacturing-Market-Expected-to-Triple-by-2035-Analysis-of-Growth-Opportunities-in-Emerging-Therapies.html.

67. GlobeNewswire. Single-use bioreactors market share to rise at 9.0% CAGR, to reach USD 10.42 Billion by 2034: PMR. Dec 17, 2024. https://www.globenewswire.com/news-release/2024/12/17/2998140/0/en/Single-Use-Bioreactors-Market-Share-to-Rise-At-9-0-CAGR-To-Reach-USD-10-42-Billion-by-2034-PMR.html.

68. Businesswire. Cell therapy manufacturing industry forecast to 2035: high demand for T-cell therapies to generate 45% of clinical need by 2035. Apr 8, 2025. https://www.businesswire.com/news/home/20250408189477/en/Cell-Therapy-Manufacturing-Industry-Forecast-to-2035-High-Demand-for-T-Cell-Therapies-to-Generate-45-of-Clinical-Need-by-2035---ResearchAndMarkets.com.

69. Aguiar T. Is early automation the key to scalable cell therapy manufacturing. *Cell and Gene* May 8, 2025. https://www.cellandgene.com/doc/is-early-automation-the-key-to-scalable-cell-therapy-manufacturing-0001.

70. Stenberg C. Cell and gene therapy manufacturing challenges and solutions. *Contract Pharma* Feb 7, 2025. https://www.contractpharma.com/exclusives/cell-and-gene-therapy-manufacturing-challenges-solutions.

71. BioPharma APAC. Why cell therapy systems are going automatic: a new era of manufacturing. Apr 22, 2025. https://biopharmaapac.com/report/134/6254/why-cell-therapy-systems-are-going-automatic-a-new-era-of-manufacturing.html.

72. Williamson K. Challenges and opportunities in cell and gene therapy manufacturing. *Pharma Focus America* Aug 19, 2024. https://www.pharmafocusamerica.com/articles/challenges-opportunities-cell-gene-therapy-manufacturing.

73. Nix B. Navigating AI patent protection: strategic considerations for biotech companies. *JMIN* Feb 28, 2025. https://jmin.com/navigating-ai-patent-protection-strategic-considerations-for-biotech-companies.

74. Sethi D. AI's next horizon: cell and gene therapy manufacturing. *Technology Networks* Mar 13, 2025. https://www.technologynetworks.com/biopharma/blog/ais-next-horizon-cell-and-gene-therapy-manufacturing-396831.

75. Octava. 2025 Trends in edge computing security. Dec 12, 2024. https://www.otava.com/blog/2025-trends-in-edge-computing-security/#:~:text=Edge%20computing%20security%20is%20a,from%20just%2010%25%20in%202018.

76. Mann E. Cell and gene therapy fill-finish: processes, challenges, and innovations. *Cell and Gene* https://www.cellandgene.com/topic/cell-gene-therapy-fill-finish.

AFFILIATIONS

Will Rosellini, President, CytoImmune Therapeutics, Inc., Duarte, CA, USA

Oscar Chow, Senior Patent Analyst Manager and **Oscar Hernandez**, IP Analyst, PatentVest, Inc., Addison, TX, USA

AUTHORSHIP & CONFLICT OF INTEREST

Contributions: The named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None.

Disclosure and potential conflicts of interest: The authors have no conflicts of interest.

Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article.

ARTICLE & COPYRIGHT INFORMATION

Article source: Invited; externally peer reviewed.

Submitted for peer review: Jun 5, 2025.

Revised manuscript received: Jul 22, 2025.

Publication date: Aug 12, 2025.